Wednesday, June 8, 2016

Omicia Finds $23M For Precision Medicine

Oakland-based Omicia, which is developing clinical genome interpretation and reporting software for the personalized medicine market, said this morning that it has raised $23M in a Series B funding. The funding came from UPMC Enterprises, Roche Venture Fund, LDV Partners, Ping An Ventures, an un-named, "large genomics investor", along with ARTIS Ventures, Acadia Woods Partners and Buchanan Investments. Omicia is led by CEO Matt Tindall. More information »